A5079186779- Nanoparticle-Based Drug Delivery
- Peptidase Inhibition and Analysis
- RNA Interference and Gene Delivery
- Biochemical and Molecular Research
- Chemical Synthesis and Analysis
- melanin and skin pigmentation
- Neuropeptides and Animal Physiology
- Biochemical Analysis and Sensing Techniques
- Advanced biosensing and bioanalysis techniques
- Lung Cancer Research Studies
- Chemokine receptors and signaling
- Monoclonal and Polyclonal Antibodies Research
- Click Chemistry and Applications
- Mast cells and histamine
- Receptor Mechanisms and Signaling
National Institute of Oncology
2022-2024
Semmelweis University
2023-2024
Targeted tumour therapy has proved to be an efficient alternative overcome the limitations of conventional chemotherapy. Among several receptors upregulated in cancer cells, gastrin-releasing peptide receptor (GRP-R) recently emerged as a promising target for imaging, diagnosing and treatment due its overexpression on cancerous tissues such breast, prostate, pancreatic small-cell lung cancer. Herein, we report vitro vivo selective delivery cytotoxic drug daunorubicin prostate breast cancer,...
Malignant melanoma is one of the most aggressive and resistant tumor types, with high metastatic properties. Because lack suitable chemotherapeutic agents for treatment, 5-year survival rate patients regional distant metastases lower than 10%. Targeted therapy that provides several promising results might be a good option treatment malignant melanomas. Our goal was to develop novel melanoma-specific peptide–drug conjugates targeted therapy. Melanocortin-1-receptor (MC1R) cell surface...
Chemotherapy is still one of the main therapeutic approaches in cancer therapy. Nevertheless, its poor selectivity causes severe toxic side effects that, together with development drug resistance tumor cells, results a limitation for application. Tumor-targeted delivery possible choice to overcome these drawbacks. As well as monoclonal antibodies, peptides are promising targeting moieties delivery. However, peptide–drug conjugates (PDCs) big challenge. The reason that have be stable...
Chemotherapy is still a leading therapeutic approach in various tumor types that often accompanied by poor prognosis because of metastases. PEGylated liposomes with CREKA targeting moiety are well-known agents, especially highly metastatic experimental models. specifically targets tumor-associated ECM, which present at the primary, as well sites. To better understand function moieties, we decided to design liposome formulations different amounts attached their DSPE-PEG molecules. Moreover,...
Malignant melanoma is one of the most aggressive and resistant tumor types which often accompanied by poor prognosis when spread to nearby or distant tissues. Even though an increasing number second-line therapies are available for cancer patients, 5-year survival rate patients with regional metastases still rather low. Therefore, there urgent need develop new, highly efficient treatments. Melanocortin-1-receptor (MC1R) a cell surface receptor α-MSH. It responsible melanogenesis shown be...
Targeted tumour therapy has proved to be an efficient alternative overcome the limitations of conventional chemotherapy. The upregulation bombesin receptor 2 (BB2) in several malignancies and advantages offered by peptide drug conjugates over antibody terms production targeting motivated us synthesise test armed with tubulin binder monomethyl auristatin E. widely used Val-Cit-PABC was initially included as cathepsin cleavable self-immolative linker for release free drug. However, poor...